MAIA Biotechnology (MAIA) announced dosing of the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer. The trial’s entry into another continent marks a milestone for MAIA, opening a significantly larger patient pool for its evaluations of ateganosine. Screening for the trial is ongoing in Europe and Asia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA: